DCIS and axillary nodal evaluation: compliance with national guidelines by unknown
RESEARCH ARTICLE Open Access
DCIS and axillary nodal evaluation:
compliance with national guidelines
Katrina B. Mitchell1, Heather Lin2, Yu Shen2, Alfred Colfry1, Henry Kuerer1, Simona F. Shaitelman3,
Gildy V. Babiera1 and Isabelle Bedrosian1*
Abstract
Background: The National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology
(ASCO) provide guidelines regarding axillary nodal evaluation in ductal carcinoma in situ (DCIS), but data regarding
national compliance with these guidelines remains incomplete.
Methods: We conducted a retrospective review of the National Cancer Data Base (NCDB) analyzing all surgical
approaches to axillary evaluation in patients with DCIS. Logistic regression analysis was used to assess the
multivariate relationship between patient demographics, clinical characteristics, and probability of axillary evaluation.
Results: We identified 88,083 patients diagnosed with DCIS between 1998 and 2011; 31,912 (37%) underwent total
mastectomy (TM) and 55,349 (63%) had breast conserving therapy (BCT). Axillary evaluation increased from 44.4% in
1998 to 63.3% in 2011. In TM patients, axillary evaluation increased from 74.3% in 1998 to 93.4% in 2011. This correlated
with an increase in sentinel lymph node biopsy (SLNB) from 24.3 to 77.1%, while ALND decreased from 50.0 to 16.3%
(p <0.01). In BCT patients, evaluation increased from 20.1 to 43.9%; SLNB increased from 7.2 to 39.4% and ALND
decreased from 12.9 to 4.5%. Factors associated with axillary nodal evaluation in BCT patients included practice
type and facility location. Among TM patients, use of axillary lymph node dissection (ALND) for axillary staging
was associated with earlier year of diagnosis, black race, and older age, as well as community practice setting and
practice location in the Southern US.
Conclusions: Compliance with national guidelines regarding axillary evaluation in DCIS remains varied. Practice
type and location-based differences suggest opportunities for education regarding the appropriate use of axillary
nodal evaluation in patients with DCIS.
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Background
Ductal carcinoma in situ (DCIS) currently represents
20% of breast cancers, affecting approximately 65,000
women per year [1, 2]. Since the early 1970s, the incidence
of DCIS has increased from 1.8 per 100,000 women to
32.5 per 100,000 women in the mid-2000s [3]. This repre-
sents a fivefold increase in diagnoses over time, and largely
has resulted from widespread adoption of screening mam-
mography: more than 80% of lesions are detected through
this modality [4]. Though DCIS carries a low cumulative
20-year breast cancer specific mortality rate of 3.3%, its
diagnosis nevertheless may trigger potentially aggressive in-
terventions with associated complications [5]. In particular,
axillary interventions, even limited intervention through
use of sentinel node biopsy, carry risk of long term seque-
lae such as chronic pain, decreased strength, edema, and
sensory disorder from sentinel lymph node biopsy [6].
Though DCIS treatment traditionally has involved a com-
bination of radiation, endocrine therapy, and surgery, atten-
tion is increasingly being directed towards analyzing the
appropriateness of surgical interventions. In particular, the
rate and appropriateness of axillary lymph node evaluation
in surgical procedures for DCIS recently has been investi-
gated [7–11]. Many of these studies acknowledged that
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of patients do not require axillary evaluation, selected cases
may warrant the procedure.
Guidelines set forth by the National Comprehensive
Cancer Network (NCCN) do not recommend axillary
lymph node evaluation for patients undergoing breast
conserving therapy (BCT); it advises that mastectomy
(TM) patients may or may not undergo sentinel node
biopsy (SLNB). The NCCN further states that axillary
lymph node dissection (ALND) should not be performed
for DCIS in the absence of invasive cancer or proven
axillary disease, but does note that invasive cancer may
be found at the time of surgery in a small percentage of
patients. Because of this, the NCCN recommends that
SLNB should be “strongly considered” with mastectomy or
“excision in an anatomic location compromising the per-
formance of a future sentinel lymph node procedure.” [12].
Similarly, in its 2014 summary of guidelines addressing
sentinel lymph node biopsy for patients with early-stage
breast cancer, ASCO reaffirmed that clinicians may offer
SLNB to patients undergoing a mastectomy (www.asco.org/
guidelines/snbbreast). It does not recommend SLNB for
BCT unless the tumor is in a location that may preclude
future node sampling due to lymphatic disruption during
the index procedure; DCIS diagnosed as a mass on imaging
or clinical exam; or, large volume DCIS [13].
Overall, the majority of DCIS lesions would not fall
within these guidelines and as such axillary evaluation
would be considered over treatment. The purpose of this
study was to evaluate adherence with these national guide-
lines and identify areas in which clinical care and education
may be focused to improve compliance and reduce un-
necessary axillary nodal evaluation. This will prevent both
under and overtreatment of DCIS, eliminating unnecessary
patient morbidity and reducing health care costs.
Methods
Data source
The National Cancer Data Base (NCDB) represents a
collaborative repository of patient data drawn from the
American Cancer Society (ACS) and the Commission on
Cancer (COC) of the American College of Surgeons
(https://www.facs.org/quality-programs/cancer/ncdb) Since
1989, the NCDB has functioned as a nationwide oncology
outcomes database for more than 1,500 COC-accredited
cancer programs in the United States (US) and Puerto Rico,
and contains approximately 29 million total records. Sev-
enty percent of all newly-diagnosed cancers are captured at
the institutional level and reported to the NCDB. Since
patient level identifiers are not available to NCDB users,
this study was exempted from IRB review and approval.
Selection of analytic cohort
From the total 2,720,347 patients in the dataset, 88,083
female patients who met the following DCIS criteria
were included in the final analytic cohort: 1) had a histology
code of 8010, 8020, 8022, 8201, 8230, 8500, 8501, 8503,
8514, 8521, 8522, 8523, 2) were clinically designated as
TisN0M0, 3) were pathologically confirmed TisN0M0, 4)
had no history of other prior cancers and 5) did not receive
chemotherapy. Patients whose insurance status was un-
known or who were treated at “other specified types of
cancer programs” were excluded from the analysis.
Statistical analysis
SLNB was defined as 1–4 lymph nodes removed, while
ALND was defined as ≥5 lymph nodes removed. Univariate
analysis was performed to evaluate the association between
each variable and axillary evaluation, using chi-square tests
for categorical variables and t-test/ANOVA or the
counterparts of the non-parametric approaches (Wilcoxon
rank-sum or Kruskal-Wallis) for continuous variables [14].
Logistic regression analysis [15] was used to assess the
multivariate relationship between patient demographic,
clinical characteristics and the probability of axillary evalu-
ation. Age was categorized into quartiles. SAS version 9.2
and S-Plus version 8.04 was used to carry out the compu-
tations for all analyses.
Results
Of the 88,083 patients diagnosed with DCIS from 1998
to 2011 who met inclusion criteria for our analysis,
31,912 of these patients (37%) underwent total mastectomy
(TM), and 55,349 patients (63%) underwent BCT. For the
entire cohort of patients evaluated, axillary lymph node
evaluation (either ALND or SLNB) increased from 44.4% in
1998 to 63.3% in 2011, with an increasing proportion of
SLNB utilized over time: ALND decreased from 29.5 to
9.1%, while SLNB increased from 14.9 to 54.2% (p <0.01).
Figure 1 illustrates this trend.
Among patients who underwent TM, a similar trend
of overall increased axillary evaluation from 74.3% in
1998 to 93.4% in 2011 was demonstrated. As with the
entire cohort, this correlated with a concomitant increased
utilization of SLNB: ALND decreased from 50.0 to 16.3%,
while SLNB increased from 24.3 to 77.1% (p <0.01). Figure 2
illustrates this trend.
In the TM cohort, younger age was significantly associ-
ated with axillary evaluation: 88.5% of 18–46 years-old
patients underwent an axillary procedure, compared with
82.1% of those older than 65 (p <0.01) (Table 1). Treat-
ment at an academic/research program also was signifi-
cantly associated with axillary evaluation, with 88.1% of
patients undergoing a procedure in those institutions,
versus 86% at a comprehensive community cancer pro-
gram and 81% at a community cancer program (p <0.01).
Although facility location in the South had a higher rate of
axillary evaluation as compared with the other geographic
areas (p = 0.02), absolute differences between geographic
Mitchell et al. BMC Surgery  (2017) 17:12 Page 2 of 10
locations were relatively small (2%). Overlapping lesions
underwent the highest rate of axillary evaluation versus
the lowest at the nipple/areola (88 vs. 79.1%) (p <0.01).
Tumors <1 cm had lower axillary evaluation rates com-
pared with tumors >5 cm (83.5 vs. 92.8%, p <0.01).
The multivariate analysis of the TM cohort (Table 2)
was similar to the results of the univariate analysis. When
compared with academic/research programs, community
cancer programs as well as comprehensive community
cancer programs were less likely to evaluate the axilla (OR
0.63 {95% CI 0.54–0.75}) and (OR 0.84 {95% CI 0.76–
0.93}), respectively. Tumors in the nipple/areolar region
remained least likely to receive axillary evaluation
compared with overlapping tumors (OR 0.57 {95% CI
0.38–0.88}). Smaller tumors (<1 cm) were associated
with lower axillary sampling compared with larger tumors
(>5 cm) (OR 0.44 {95% CI 0.37–0.52}). Compared with
patients diagnosed with DCIS in 2011, those diagnosed in
2000 were the least likely to undergo axillary evaluation
(OR 0.15 {0.12–0.20}).
To better understand how the patient demographic
and provider characteristics influence the use of SLNB
versus ALND in the TM cohort, a sub-group analysis
was conducted (Table 3). The results showed that year
of diagnosis was significantly associated with ALND
utilization, with the highest rate in 1998 (67.3%) and
lowest in 2011 (17.4%) (p = <0.01). Black race was signifi-
cantly associated with ALND, as 35.1% of black patients
underwent ALND versus 26.4% of white patients and
21% of women of other races (p <0.01). In contrast to
the entire TM cohort, in which younger women were
more likely to undergo axillary evaluation, age >65 was
significantly associated with the more invasive ALND
procedure (32.6 vs 25.2% for 18–46 years, p <0.01)
compared to SLNB. Facility location in the South was
significantly associated with ALND compared to facil-
ities in the West, where the ALND rate was lowest
(29.8 vs 23.7%, p <0.01), as were community (32.6%)
versus academic/research programs (26.2%) (p <0.01).
In terms of tumor characteristics, locations in the nipple/
areola were significantly associated with ALND (37.2%,
p <0.01), as were those >5 cm in size (27.4 vs 25.2% for
tumor <1 cm, p <0.01).
The cohort of 55,349 patients who underwent BCT
was analyzed separately (Fig. 3). Overall, axillary
evaluation increased from 20.1% in 1998 to 43.9% in
Fig. 1 Trend in type of axillary evaluation over time among all patients
Fig. 2 Trend in axillary evaluation over time among patients who underwent mastectomy
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Table 1 Univariate analysis of axillary evaluation and patient characteristics among those who underwent mastectomy
Mastectomy Cohort (n = 31,912) Breast Conservation Cohort (n = 55,349)
Variable Yes No p-Value Yes No p-Value
Year of Diagnosis 1998 828(74.4%) 285(25.6%) <0.01 265(20.1%) 1051(79.9%) <0.01
1999 821(72.8%) 306(27.2%) 303(18.8%) 1311(81.2%)
2000 838(70.1%) 358(29.9%) 369(21.1%) 1378(78.9%)
2001 896(73.7%) 319(26.3%) 437(23.6%) 1412(76.4%)
2002 895(72.4%) 342(27.6%) 503(24.1%) 1582(75.9%)
2003 1146(74.9%) 385(25.1%) 819(26.5%) 2272(73.5%)
2004 1203(82.1%) 262(17.9%) 895(28.5%) 2250(71.5%)
2005 1345(82.5%) 286(17.5%) 1008(29.9%) 2365(70.1%)
2006 1544(85.1%) 270(14.9%) 1216(32.3%) 2553(67.7%)
2007 1939(87.5%) 278(12.5%) 1539(34.1%) 2979(65.9%)
2008 3471(91.3%) 329(8.7%) 2611(36.9%) 4457(63.1%)
2009 4142(91.3%) 397(8.7%) 3041(37.9%) 4981(62.1%)
2010 4151(93.5%) 287(6.5%) 2904(43%) 3851(57%)
2011 4286(93.4%) 303(6.6%) 3069(43.9%) 3928(56.1%)
Race Black 3144(86.5%) 491(13.5%) 0.52 2087(34.1%) 4039(65.9%) 0.02
White 22682(86.2%) 3638(13.8%) 15954(34.5%) 30246(65.5%)
Other 1335(85.3%) 230(14.7%) 761(31.9%) 1628(68.1%)
Age 18–46 7089(88.5%) 918(11.5%) <0.01 5023(34.8%) 9392(65.2%) <0.01
47–55 7440(87.2%) 1096(12.8%) 5137(34.9%) 9584(65.1%)
56–65 6549(86.8%) 992(13.2%) 4743(35.6%) 8594(64.4%)
>65 6427(82.1%) 1401(17.9%) 4076(31.7%) 8800(68.3%)
Facility Type Community Cancer Program 2175(81%) 511(19%) <0.01 2133(36.4%) 3731(63.6%) <0.01
Comprehensive Community Cancer Program 16873(86%) 2757(14%) 12474(36.6%) 21632(63.4%)
Academic/Research Program 8457(88.1%) 1139(11.9%) 4372(28.4%) 11007(71.6%)
Facility Location Midwest 6742(86.2%) 1079(13.8%) <0.01 4169(31.4%) 9128(68.6%) <0.01
Northeast 5267(86.7%) 810(13.3%) 3612(27.9%) 9319(72.1%)
South 10642(86.8%) 1623(13.2%) 7738(41.2%) 11023(58.8%)
West 4854(84.4%) 895(15.6%) 3460(33.4%) 6900(66.6%)
Primary Site Nipple areolar 223(79.1%) 59(20.9%) <0.01 94(26.7%) 258(73.3%) <0.01
Central 1766(85.1%) 310(14.9%) 1047(30.7%) 2368(69.3%)
Upper inner 1883(86.5%) 294(13.5%) 1629(34.1%) 3153(65.9%)
Lower inner 1672(87.3%) 244(12.7%) 1123(32.9%) 2288(67.1%)
Upper outer 7503(86.4%) 1185(13.6%) 7413(36.7%) 12801(63.3%)
Lower outer 1861(86.8%) 284(13.2%) 1240(33.9%) 2418(66.1%)
Axillary tail 31(86.1%) 5(13.9%) 51(48.1%) 55(51.9%)
Overlapping lesion 6113(88%) 835(12%) 3723(34.2%) 7175(65.8%)
NOS 6453(84.4%) 1191(15.6%) 2659(31.2%) 5854(68.8%)
Tumor Size ≤1 cm 4921(83.5%) 970(16.5%) <0.01 5605(30.3%) 12878(69.7%) <0.01
>1 cm, ≤2 cm 5846(88.7%) 745(11.3%) 4903(40.7%) 7139(59.3%)
>2 cm, ≤3 cm 1762(90%) 195(10%) 940(43.9%) 1199(56.1%)
>3 cm, ≤4 cm 1376(89.6%) 159(10.4%) 647(45.3%) 781(54.7%)
>4 cm, ≤5 cm 1178(91.7%) 106(8.3%) 363(45.1%) 441(54.9%)
>5 cm 2526(92.8%) 196(7.2%) 535(45.2%) 648(54.8%)
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2011 (Table 1). Within this group, ALND decreased
from 12.9 to 4.5%, while SLNB increased from 7.2 to
39.4%. Similar to TM patients, younger patient under-
going BCT were more likely to have their axilla evalu-
ated than older patients (p <0.01). BCT patients were
least likely to undergo axillary evaluation at academic/
research programs (28.4%) versus community cancer
programs (36.4%) and comprehensive community cancer
programs (36.6%), (p <0.01). Facility locations in the
Northeast demonstrated the lowest axillary evaluation
rate (27.9%), with the South area reporting the highest
rate (41.2%) (p <0.01). As with the TM cohort, tumors
located near the nipple were the least likely to undergo
axillary evaluation (26.7%) versus tumors in the axillary
tail (48.1%) (p <0.01). Tumors <1 cm were less likely to
undergo axillary evaluation (30.3%) than tumors >3 cm
(45.3%).
A multivariate analysis of axillary evaluation among BCT
patients showed differences by year of diagnosis, facility
type and location, as well as patient and tumor characteris-
tics (Table 4). Patients undergoing a surgery procedure in
1999 were the least likely of all years to undergo axillary
evaluation, compared with 2011 (OR 0.29 {95% CI 0.24–
0.35}). Academic/research programs and facility locations
in the Northeast were least likely to evaluate the axilla com-
pared to non-academic cancer centers and centers in the
South (OR 0.73 {95% CI 0.69–0.77}) and (OR 0.58 {95% CI
0.55–0.62}), respectively. Tumors <1 cm in size were least
likely to undergo axillary evaluation compared with
tumors >5 cm (OR 0.50 {95% CI 0.44–0.57}). Black
women were 15% less likely to undergo axillary evaluation
compared to white women (OR 0.85 {95% CI 0.79–0.92}),
as were older women with a 1% decrease in probability of
axillary evaluation per year increase in age.
Table 2 Multivariate analysis of axillary evaluation and patients’ characteristics among those who underwent mastectomy
Variable Odds Ratio Lower CL Upper CL p-Value
Age Per year increase 0.99 0.98 0.99 <0.01
Facility Type (ref = Academic/Research Program) Community Cancer Program 0.63 0.54 0.75 <0.01
Comprehensive Community Cancer Program 0.84 0.76 0.93
Primary Site (ref = Overlapping lesion) Nipple areolar 0.57 0.38 0.88 0.01
Central 0.82 0.68 0.99
Upper inner 0.91 0.76 1.11
Lower inner 1.03 0.83 1.26
Upper outer 1.00 0.87 1.13
Lower outer 0.88 0.72 1.06
Axillary tail 2.11 0.47 9.36
NOS 0.83 0.72 0.95
Tumor Size (ref= > 5 cm) ≤1 cm 0.44 0.37 0.52
>1 cm, ≤2 cm 0.68 0.58 0.81
>2 cm, ≤3 cm 0.74 0.60 0.92
>3 cm, ≤4 cm 0.72 0.57 0.90
>4 cm, ≤5 cm 0.93 0.72 1.20
Year of Diagnosis (ref = 2011) 1998 0.19 0.15 0.24 <0.01
1999 0.19 0.15 0.25
2000 0.15 0.12 0.20
2001 0.21 0.17 0.27
2002 0.18 0.14 0.22
2003 0.21 0.17 0.26
2004 0.33 0.26 0.42
2005 0.35 0.28 0.44
2006 0.40 0.32 0.49
2007 0.53 0.43 0.66
2008 0.76 0.62 0.92
2009 0.72 0.60 0.88
2010 1.06 0.86 1.29
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Table 3 Association between patient characteristics and type of axillary evaluation in mastectomy patients
Variable ALND SLNB p-Value














Race Black 1103(35.1%) 2041(64.9%) <0.01
White 5978(26.4%) 16704(73.6%)
Other 293(21.9%) 1042(78.1%)




Facility Type Community Cancer Program 710(32.6%) 1465(67.4%) <0.01
Comprehensive Community Cancer Program 4527(26.8%) 12346(73.2%)
Academic/Research Program 2218(26.2%) 6239(73.8%)




Primary Site Nipple areolar 83(37.2%) 140(62.8%) <0.01
Central 474(26.8%) 1292(73.2%)
Upper inner 473(25.1%) 1410(74.9%)
Lower inner 420(25.1%) 1252(74.9%)
Upper outer 2167(28.9%) 5336(71.1%)
Lower outer 477(25.6%) 1384(74.4%)
Axillary tail 7(22.6%) 24(77.4%)
Overlapping lesion 1559(25.5%) 4554(74.5%)
NOS 1795(27.8%) 4658(72.2%)
Tumor size ≤1 cm 1241(25.2%) 3680(74.8%) 0.01
>1 cm, ≤2 cm 1415(24.2%) 4431(75.8%)
>2 cm, ≤3 cm 411(23.3%) 1351(76.7%)
>3 cm, ≤4 cm 326(23.7%) 1050(76.3%)
>4 cm, ≤5 cm 285(24.2%) 893(75.8%)
>5 cm 693(27.4%) 1833(72.6%)
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Discussion
The results of this study demonstrate an increased rate
of axillary evaluation in DCIS over time, from 44.4% of
patients undergoing such a procedure in 1998 to 63.3%
in 2011. Despite a favorable trend of increased SLNB
(14.9 to 54.2%) with decreased ALND (29.5 to 9.1%)
over the time frame of our study, practice patterns
nevertheless do not adhere to NCCN and ASCO guide-
lines regarding axillary evaluation, and demonstrate vari-
ation by patient ages, tumor size, geographic location,
and practice facility type.
Among patients undergoing BCT in 2011, the most
recent year of data capture, the axillary evaluation rate
of 43.9% (of which 4.5% is ALND) is concerning. The
NCCN and ASCO recommend SLNB only in cases of
tumor location precluding future sentinel lymph node
mapping, or large volume or mass-associated DCIS
[12, 13]. Tumor location that precludes future lymph
node sampling is accepted as those tumors located in
the central breast, upper outer quadrant, or axillary
tail [16]. Overall, these locations accounted for only
15.5% of SLNB in the BCT cohort. Tumors >5 cm in
size accounted for only 4.1% of the cohort. Thus, in
most of the women in this cohort undergoing BCT, we
could not identify clear indication for SLN biopsy.
Though national guidelines recommend SLNB in TM,
a significant proportion of patients did not receive any
axillary evaluation at all. In terms of patient demographics,
those who were not black or were younger in age were less
likely to receive axillary evaluation. It is possible that
younger patients underwent less morbid staging technique
or were perceived as having less aggressive disease than
older or black patients. Community cancer programs or
facilities located in the western United States were also
less likely to evaluate the axilla, which represents regional
variation that we saw among all cohorts. Finally, patients
with smaller tumors or those located near the nipple/areo-
lar complex understandably underwent the least frequent
axillary evaluation, reflecting a potential surgical provider
bias that these tumors would be least likely to demon-
strate nodal involvement.
While national guidelines recommend SLNB for TM,
the ALND rate of 16.3% in our cohort warrants further
investigation. Our subgroup analysis of SLNB vs. ALND
in TM demonstrated important differences from the
overall axillary evaluation group. The total cohort and
sub-groups both did show decreased rates of ALND
over time. However, our finding that age >65 had the
highest rate of ALND is concerning, given the known
co-morbidities associated with this procedure and the
decreased likelihood of aggressive disease in this age
distribution compared with younger women. The sub-
group analysis showed that community programs were
more likely to utilize ALND than SLNB, potentially
reflecting the slower adoption of minimally invasive
axillary staging in this setting. The highest rate of ALND in
relationship to tumor site and size were in the nipple/areolar
region and in tumors >5 cm. This may have reflected failure
of intraoperative mapping and/or ALND completed
due to high clinical suspicion. Unfortunately, our data
are unable to capture this decision-making process.
Other factors demonstrating significant relationship
to guideline discordant axillary evaluation in the TM
and BCT cohorts included facility type and location.
Academic programs were most likely to demonstrate
compliance with national guidelines, whereas facility lo-
cations in the south were least likely to be compliant.
Geographic variation may reflect regional differences in
practices that we are unable to capture in our data, but
do suggest that a renewed emphasis on adherence with
national guidelines, rather than regional practice pat-
terns in the surgical care of DCIS is required.
Our results demonstrate both similarities and differences
when compared with other recent studies investigating axil-
lary evaluation in DCIS. Though our rates of BCT for DCIS
are similar to other recent studies, we demonstrate higher
Fig. 3 Trend in axillary evaluation over time in patients who underwent breast conservation
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rates of axillary evaluation in DCIS (63.3%). This may
be reflective of our larger and more inclusive NCDB
data set. Using the Perspective database, Coromilas et
al., showed a 29.2% rate of axillary evaluation [11]. This
database primarily captures patients treated at urban
and teaching hospitals and has a preponderance of fa-
cilities located in the Southern United States. In con-
trast, the NCDB, with its national catchment area,
provides broader geographic representation and also in-
cludes smaller community practices and as such is
likely to be much more representative of the national
practice. Porembka et al. studied the 1998–2002 SEER
database and showed a 28% rate of axillary evaluation;
however, their study (similar to Coromilas et al.), repre-
sented a much smaller population since SEER captures
fewer cancer patients than NCDB, and therefore again
Table 4 Multivariate analysis of axillary evaluation and patients’ characteristics among patients who underwent breast conservation
Variable Odds Ratio Lower CL Upper CL p-Value
Age Per year increase 0.99 0.99 0.99 <0.01
Facility Location (ref = South) Midwest 0.71 0.67 0.76 <0.01
Northeast 0.58 0.55 0.62
West 0.72 0.67 0.77








Primary Site (ref = Axillary tail) Nipple areolar 0.39 0.22 0.69 <0.01
Central 0.54 0.33 0.89
Upper inner 0.60 0.37 0.98
Lower inner 0.58 0.35 0.94
Upper outer 0.69 0.43 1.13
Lower outer 0.60 0.37 0.98
Axillary tail 0.61 0.373 0.98
Overlapping lesion 0.56 0.34 0.91
Race (ref = White) Black 0.85 0.79 0.92 <0.01
Other 0.81 0.73 0.90
Tumor Size (ref= > 5 cm) <1 cm 0.50 0.44 0.57 <0.01
>1 cm, ≤2 cm 0.69 0.71 0.90
>2 cm, ≤3 cm 0.89 0.77 1.03
>3 cm, ≤4 cm 0.96 0.82 1.13
>4 cm, ≤5 cm 0.97 0.81 1.17
Year of Diagnosis (ref = 2011) 1998 0.30 0.25 0.36 <0.01
1999 0.29 0.24 0.35
2000 0.32 0.27 0.38
2001 0.35 0.30 0.41
2002 0.37 0.32 0.43
2003 0.49 0.43 0.55
2004 0.55 0.49 0.62
2005 0.56 0.50 0.62
2006 0.62 0.56 0.69
2007 0.66 0.60 0.73
2008 0.77 0.71 0.83
2009 0.79 0.73 0.85
2010 1.02 0.94 1.10
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SEER data may not reflect the trends we observed in a
larger, more nationally representative group [10].
Worni et al. utilized the SEER database to study
trends in treatment patterns for DCIS, focusing on
disease free survival and overall survival [7]. However, they
did not highlight whether treatment patterns were compli-
ant with national guidelines, nor detail the variables asso-
ciated with use of axillary staging. Given the potential to
over treat DCIS patients with unwarranted axillary sur-
gery, and the long term complications associated with
axillary intervention, understanding factors impacting
guideline discordant care is of importance in order to
develop strategies for education and improvement in
standardization of surgical approaches to DCIS.
Miller et al. recently reported on DCIS and axillary
evaluation using the NCDB database, looking specifically
at which factors were predictive of tumor upstaging and
the relationship to appropriate utilization of SLNB [8].
While our study population has overlap with the recent
paper by Miller et al., in order to best capture compliance
with axillary surgery for DCIS patients, we excluded from
our analysis the subset of DCIS patients upgraded to inva-
sive cancer, for whom SLNB is concordant with care guide-
lines. Similarly, a study by Nicholson et al., described
practice patterns for DCIS care in the United Kingdom and
again provided information on axillary staging, but also
included patients upgraded to invasive cancer [9]. While
these studies collectively provide insight on practice
patterns, including axillary interventions, in DCIS patients,
our study, focused on the subset with pure DCIS without
upgrade, is best positioned to address the question of
compliance with axillary staging and hence rates of
overtreatment of DCIS patients. We emphasize that
our findings provide a benchmark for current practice
patterns regarding DCIS and axillary evaluation in the
United States, and offer opportunity for improvement
in compliance with guidelines.
Limitations
There are several limitations of our paper. It is a retro-
spective review that allows limited analysis of pathologic
subtypes of DCIS that may warrant more aggressive sur-
gical intervention. We have no data regarding clinical
exam or clinical intraoperative judgment that may have
led providers to undertake axillary evaluation discordant
with national guidelines. Because the NCDB does not
have a reliable variable to distinguish between ALND
and SLNB, we assumed that lymph node sampling of >4
nodes represented a formal ALND procedure, in line
with other similar studies and based on data demon-
strating that the majority of women will not have more
than 4 SLN [17, 18]. This methodology to distinguish
between SLNB and ALND likely resulted in some over-
representation of the number of ALND procedures
performed. We emphasize this is a significant limitation
of our data, though we believe this bias should be small
since it is uncommon for greater than four sentinel
lymph nodes to exist.
Conclusions
We report significant rates of non-compliance with na-
tional guidelines in the surgical treatment of DCIS, both
in the appropriate performance of axillary evaluation
and in use of appropriate technique (ALND versus
SLNB). The results of this study suggest that increased
emphasis be placed on adherence to national guidelines
among different facility practice locations and types.
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